GlassScriptPhysician profile
Wafeeqa Azeem
NPI 1437548245
$1,286.02
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.73 · 2022: $123 · 2023: $651 · 2024: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $543.77 | 2023-2024 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.61 | 2021-2024 | Relistor |
| Boston Scientific Corporation | $110.24 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Protega Pharmaceutials INC | $103.87 | 2023-2024 | Roxybond |
| Scilex Pharmaceuticals INC. | $64.18 | 2023 | Ztlido |
| Masimo Corporation | $61.61 | 2023 | Set and Rainbow Set |
| Forte Bio-Pharma LLC | $46.32 | 2023-2024 | Prolate, Nalocet |
| Zimvie INC. | $26.97 | 2022 | |
| Avanos Medical | $20.67 | 2022 | |
| Nalu Medical, INC. | $20.25 | 2023 | Nalu Neurostimulation System |
| Depuy Synthes Sales INC. | $18.41 | 2022 | |
| Orthogenrx INC. | $14.74 | 2021 | |
| Glaxosmithkline, LLC. | $14.50 | 2022 | |
| Abbott Laboratories | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wafeeqa Azeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.